Citadel Advisors
ABEO icon

Citadel Advisors’s Abeona Therapeutics ABEO Stock Holding History

Citadel Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Sell
27,000
-57,000
-68% -$285K ﹤0.01% 11858
2025
Q4 		$443K Buy
84,000
+20,600
+32% +$104K ﹤0.01% 9324
2025
Q3 		$335K Sell
63,400
-14,900
-19% -$94.5K ﹤0.01% 10112
2025
Q2 		$445K Buy
78,300
+66,100
+542% +$376K ﹤0.01% 8916
2025
Q1 		$58.1K Buy
12,200
+9,300
+321% +$50.6K ﹤0.01% 12148
2024
Q4 		$16.2K Sell
2,900
-15,100
-84% -$92.9K ﹤0.01% 13317
2024
Q3 		$114K Sell
18,000
-8,900
-33% -$46.5K ﹤0.01% 10950
2024
Q2 		$114K Buy
26,900
+15,500
+136% +$79.1K ﹤0.01% 10727
2024
Q1 		$82.7K Buy
11,400
+2,800
+33% +$17.7K ﹤0.01% 11618
2023
Q4 		$43.1K Buy
+8,600
New +$37.8K ﹤0.01% 11939
2021
Q3 		– Sell
-2,324
Closed -$91K – 13709
2021
Q2 		$91K Sell
2,324
-188
-7% -$7.67K ﹤0.01% 12987
2021
Q1 		$118K Buy
+2,512
New +$138K ﹤0.01% 12314
2020
Q3 		– Sell
-932
Closed -$68K – 9988
2020
Q2 		$68K Sell
932
-196
-17% -$13.5K ﹤0.01% 9169
2020
Q1 		$59K Sell
1,128
-720
-39% -$48.1K ﹤0.01% 8950
2019
Q4 		$151K Buy
1,848
+168
+10% +$11.9K ﹤0.01% 8360
2019
Q3 		$95K Buy
1,680
+508
+43% +$38K ﹤0.01% 8502
2019
Q2 		$140K Buy
1,172
+296
+34% +$49.6K ﹤0.01% 8390
2019
Q1 		$161K Sell
876
-224
-20% -$40.1K ﹤0.01% 8352
2018
Q4 		$196K Sell
1,100
-676
-38% -$147K ﹤0.01% 7881
2018
Q3 		$568K Buy
1,776
+616
+53% +$219K ﹤0.01% 6496
2018
Q2 		$464K Buy
+1,160
New +$507K ﹤0.01% 6490
2018
Q1 		– Sell
-456
Closed -$181K – 8202
2017
Q4 		$181K Sell
456
-24
-5% -$9.93K ﹤0.01% 7180
2017
Q3 		$205K Buy
+480
New +$129K ﹤0.01% 6651

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ABEO Position: Q1 2026 in Review

Citadel Advisors reduced its Abeona Therapeutics (ABEO) stake by 56% in Q1 2026, selling an estimated $359K and leaving 55,837 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #10910.

Citadel Advisors first reported a position in ABEO in Q4 2016 and has held it in 26 quarters since. The position peaked at $24.5M in Q3 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Citadel Advisors held 55,837 shares of Abeona Therapeutics worth $250K as of Q1 2026.
  • Citadel Advisors sold 71,781 Abeona Therapeutics shares in Q1 2026, an estimated $359K.
  • Abeona Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10910 holding.
  • Citadel Advisors first reported a position in Abeona Therapeutics in Q4 2016 and has held it in 26 quarters since.
  • Citadel Advisors's Abeona Therapeutics position peaked at $24.5M in Q3 2017.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.